# Defining a serum cortisol cutoff level post-CRH stimulation for diagnosing ACTH deficiency: A retrospective study validated by a nationwide registry

**Authors:** Tetsushi Izuchi, Shintaro Iwama, Ayana Yamagami, Tomoko Kobayashi, Koji Suzuki, Takanori Murase, Masahiko Ando, Shingo Murasawa, Kosuke Mukai, Hiroshi Takagi, Hidenori Fukuoka, Tomoko Handa, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Shigeyuki Tahara, Mitsuru Nishiyama, Kazunori Kageyama, Michio Otsuki, Hiroshi Arima

PMC · DOI: 10.3389/fendo.2026.1741709 · 2026-02-02

## TL;DR

This study identifies a new serum cortisol cutoff after a CRH stimulation test to diagnose ACTH deficiency, validated using a nationwide registry.

## Contribution

The study proposes and validates a new cortisol cutoff (12.6 µg/dL) at 30 minutes post-CRH for diagnosing ACTH deficiency.

## Key findings

- Cortisol levels were significantly higher in non-hydrocortisone patients at all time points.
- A 30-minute cutoff of 12.6 µg/dL showed high sensitivity and specificity in the discovery cohort.
- The cutoff was confirmed as optimal in an independent validation cohort with 83.7% accuracy.

## Abstract

The corticotropin-releasing hormone (CRH) stimulation test is used to diagnose adrenocorticotropic hormone (ACTH) deficiency; however, the serum cortisol cutoff value indicating impaired response on this test (18 µg/dL [approximately 500 nmol/L]) was established from the insulin tolerance test. We aimed to define a serum cortisol cutoff after CRH stimulation to diagnose ACTH deficiency.

Patients who underwent CRH stimulation at Nagoya University Hospital from 2016 to 2022 were divided retrospectively into two groups based on the need for hydrocortisone replacement at final follow-up (discovery cohort). Plasma ACTH and serum cortisol levels were measured at baseline and 30, 60, 90, and 120 minutes post-CRH administration using a current monoclonal antibody-based cortisol assay. The optimal cortisol cutoffs at each time point were determined by receiver operating characteristic (ROC) analysis. These cutoffs were validated using a nationwide disease registry in Japan (validation cohort).

In the discovery cohort (n = 227), cortisol levels were significantly higher in patients who did not receive hydrocortisone therapy (n = 136) than in those who did (n = 91) at all time points (p < 0.001). ROC analysis revealed that a 30-minute post-CRH cortisol level of 12.6 µg/dL (347.6 nmol/L) provided the best diagnostic performance to identify patients not requiring hydrocortisone therapy (sensitivity: 88.2%; specificity: 92.3%; AUC: 0.969). In the validation cohort (n = 52), this cutoff was confirmed as optimal (sensitivity: 81.0%; specificity: 86.4%; accuracy: 83.7%).

A 30-minute post-CRH serum cortisol level of 12.6 µg/dL is a useful cutoff for diagnosing ACTH deficiency.

## Linked entities

- **Chemicals:** hydrocortisone (PubChem CID 5754), cortisol (PubChem CID 5754)

## Full-text entities

- **Genes:** CRH (corticotropin releasing hormone) [NCBI Gene 1392] {aka CRF, CRH1}
- **Diseases:** ACTH deficiency (MESH:C535668)
- **Chemicals:** insulin (MESH:D007328), cortisol (MESH:D006854)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12907428/full.md

---
Source: https://tomesphere.com/paper/PMC12907428